Review Article
Pharmacological Strategies to Prevent Contrast-Induced Acute Kidney Injury
Table 10
Clinical trials comparing nebivolol with placebo and other agents for prophylaxis of contrast-induced AKI after angiography.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*Number of patient data in each group is not available. Data is shown as total patients in both groups. **Incidence of CI-AKI for intervention group data is not available. Data is shown as percentage incidence of CI-AKI decrease compared to control group. CAG: coronary angiography; CHF: congestive heart failure; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; g: gram; D5W: 5% dextrose solution; h: hour; IV: intravenous; kg: kilogram body weight; mcg: microgram; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; NSS: normal saline solution; N/2: 0.45% NaCl; po: per oral route; q12h: every 12 hours; RRT: renal replacement therapy; tid: thrice daily. |